Precigen receives fda orphan drug designation for prgn-2012 adenoverse™ immunotherapy in patients with recurrent respiratory papillomatosis (rrp)

Germantown, md., march 18, 2021 /prnewswire/ -- precigen, inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the us food and drug administration (fda) has granted orphan drug designation (odd) for prgn-2012, a first-in-class, investigational off-the-shelf (ots) adenoverse™ immunotherapy for recurrent respiratory papillomatosis (rrp).
PGEN Ratings Summary
PGEN Quant Ranking